Beigene

This is an early-stage study testing a new drug called BGB-53038, which is designed to block a specific protein (KRAS) that drives the growth of many advanced solid tumors. The main goal is to find a safe dose and see how the body handles the drug, both when given alone and when …

This is an early-stage study to test a new drug called BGB-B455 in people with advanced solid tumors that have a specific protein called CLDN6. The main goals are to find a safe and effective dose and to understand what side effects participants experience. The drug is designed t…

This early-stage trial is testing a new drug called BG-60366 in people with advanced non-small cell lung cancer that has a specific genetic change called an EGFR mutation. The drug is designed to find and break down the faulty protein that drives this type of cancer. Researchers …

This study is observing patients with a rare blood cancer called Waldenström macroglobulinemia who are taking the drug zanubrutinib. The goal is to better understand how well the drug works and what side effects patients experience in real-world settings, especially among differe…

This study is testing how well the drug zanubrutinib works and how safe it is for Chinese adults who have just been diagnosed with Waldenström's Macroglobulinemia, a rare blood cancer, and have not yet received any treatment. The goal is to gather more real-world data on the drug…

This study is testing whether a new drug combination (zanubrutinib plus an antibody) works better than the current standard treatment (lenalidomide plus rituximab) for people whose follicular or marginal zone lymphoma has returned or stopped responding to prior therapy. It will e…

This is an early-stage study testing a new oral drug called BG-68501 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see how the body processes the drug, both when given alone and when combined with…

This early-stage study is testing a new experimental drug called BGB-43395, both alone and in combination with other cancer medications, for people with advanced hormone-positive breast cancer and other solid tumors. The main goals are to find safe dosage levels and see if the dr…

This is the first time a new drug called BGB-45035 is being tested in people. The main goal is to check if it is safe and how the body processes it. The study will first give the drug to healthy volunteers at different doses. Later, a small group of adults with itchy skin conditi…

This large study is testing whether adding a new immunotherapy drug called tislelizumab to standard chemotherapy helps people with advanced bladder cancer live longer. About 420 patients who haven't had prior chemotherapy will receive either the new combination or standard treatm…

This study is testing whether a new drug called BGB-45035 can help control moderate to severe rheumatoid arthritis in adults. It's for people whose current medications aren't working well enough. Researchers will compare the drug to a placebo (inactive treatment) to see if it red…

This early-stage study is testing a new drug called BGB-11417, both by itself and combined with an existing drug (azacitidine), for people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The main goals are to find a safe and effec…

This is the first study in people testing a new experimental drug called BG-T187 for advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, see how the body processes the drug, and check for early signs that it might help s…

This study is testing an immunotherapy drug called tislelizumab for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The trial is for patients whose cancer has continued to grow despite previous treatments. Researchers want to see if this dru…